Literature DB >> 3349460

Comparison of tumor targeting of mouse monoclonal and goat polyclonal antibodies to carcinoembryonic antigen in the GW-39 human tumor-hamster host model.

R M Sharkey1, F J Primus, D Shochat, D M Goldenberg.   

Abstract

We have evaluated 4 radioiodinated mouse monoclonal anticarcinoembryonic antigen antibodies (MAbs) by using the GW-39 human colorectal tumor xenograft transplanted i.m. in immunocompetent hamsters to determine whether there were any differences in their tumor localization properties. Additional comparisons were made to affinity-purified goat anticarcinoembryonic antigen antibody. Statistically significant differences were found in the percentage/g of tumor uptake and tumor/nontumor ratios among the antibodies, so that the antibodies could be ranked according to their tumor localization properties (NP-2 greater than NP-4 = goat antibody greater than NP-1 greater than NP-3). Although statistical differences were found, tumor/nontumor values generally were not distinguished by a factor of more than 1.5, suggesting that these differences may not be biologically significant. F(ab')2 fragments of NP-2 were found to be superior to NP-4 F(ab')2 fragments, giving tumor/liver and tumor/blood ratios of 16 and 11.5, respectively, within 3 days, in comparison to 5.4 and 3.8 for NP-4 F(ab')2 fragments. Mixtures of all of the MAbs or a mixture of NP-2 and NP-4 did not improve tumor localization, in comparison to NP-2 alone. These studies suggest that mixtures of these anticarcinoembryonic antigen MAbs may not afford better tumor imaging than the use of a certain single antitumor MAb.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349460

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Optimal tumor targeting by antibodies: development of a mathematical model.

Authors:  M J Chappell; G D Thomas; K R Godfrey; A R Bradwell
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

Review 2.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Direct in vivo measurement of targeted binding in a human tumor xenograft.

Authors:  D A Berk; F Yuan; M Leunig; R K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 4.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

5.  Effects of methotrexate-carcinoembryonic-antigen-antibody immunoconjugates on GW-39 human tumors in nude mice.

Authors:  L B Shih; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study.

Authors:  R D Blumenthal; I Fand; R M Sharkey; O C Boerman; R Kashi; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor.

Authors:  O C Boerman; R M Sharkey; G Y Wong; R D Blumenthal; R L Aninipot; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p.

Authors:  R D Blumenthal; R Kashi; R Stephens; R M Sharkey; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Influence of cocktails of labeled monoclonal antibodies on the localization of antibodies in human tumor xenografts.

Authors:  Y Watanabe; K Endo; T Saga; M Koizumi; H Sakahara; T Nakai; M Hosono; Z S Yao; M Kuroki; Y Matsuoka
Journal:  Jpn J Cancer Res       Date:  1990-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.